Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rivoceranib - HLB

Drug Profile

Rivoceranib - HLB

Alternative Names: Aitan; Apatinib; Apatinib mesylate; Apatinib Mesylate Tablets; YN-968-D1

Latest Information Update: 09 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advenchen Laboratories LLC
  • Developer Elevar Therapeutics; Henan Cancer Hospital; HLB LifeScience; Hunan Cancer Hospital; Jiangsu Hengrui Medicine Co.; Peking University
  • Class Amides; Antineoplastics; Cyclopentanes; Nitriles; Pyridines; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Liver cancer; Adenoid cystic carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer
  • Preregistration Liver cancer
  • Phase III Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Adenoid cystic carcinoma; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Lung cancer; Malignant melanoma; Osteosarcoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer; Uterine cancer
  • Phase I Oesophageal cancer

Most Recent Events

  • 07 Mar 2023 Eleven Therapeutics plans to file an NDA to the US FDA for the combination of rivoceranib plus camrelizumab for the treatment of Hepatocellular carcinoma the first half of 2023
  • 07 Nov 2022 Jiangsu HengRui Medicine completes a phase I trial in Solid tumours (Late-stage disease) in China (PO) (NCT04322552)
  • 11 Oct 2022 Elevar plans to file an NDA to the US FDA for rivoceranib as a monotherapy for Adenoid cystic carcinoma by the end of 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top